We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Automated HSV1 and 2 Test Receives US Marketing Approval

By LabMedica International staff writers
Posted on 14 Jun 2015
Print article
Image: The cobas 4800 System offers fully automated sample preparation with real-time PCR technology for DNA amplification and detection (Photo courtesy of Roche).
Image: The cobas 4800 System offers fully automated sample preparation with real-time PCR technology for DNA amplification and detection (Photo courtesy of Roche).
An automated real-time polymerase chain reaction (PCR) assay for the direct detection and differentiation of HSV1 (herpes simplex virus 1) and HSV2 (herpes simplex virus 2) DNA in anogenital specimens from symptomatic patients has been certified for diagnostic use in the United States.

The [US] Food and Drug Administration (FDA) has issued 510(k) clearance, which allows marketing as a diagnostic tool, for the Roche (Basel, Switzerland) cobas HSV1 and 2 Test for the early, simultaneous detection of HSV1 and HSV2 DNA in anogenital specimens.

The Roche HSV assay was developed for use on the cobas 4800 system. This system was designed to automatically perform real-time PCR for medium- to high-throughput laboratories (up to 384 samples a day). The system incorporates fully automated sample preparation from primary vials with ready-to-use, load-and-go reagents. No thawing or mixing is required and a full run of 94 samples can be set up in less than 20 minutes.

The cobas HSV1 and 2 Test joins the expanding US system menu that currently includes the cobas CT/NG Test (chlamydia/gonorrhea), cobas HPV Test, cobas BRAF V600 Mutation Test, the cobas EGFR Mutation Test, and the cobas MRSA/SA Test.

"The addition of the cobas HSV 1 and 2 Test expands the menu for the cobas 4800 System, enabling labs to experience increased efficiency with innovative testing solutions," said Paul Brown, head of Roche Molecular Diagnostics. "This highly sensitive and specific new test for the detection of herpes simplex virus delivers reliable results to physicians for optimal patient treatment and clinical management decisions."

Related Links:

Roche


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more